Medtronic is recalling certain esophageal pH monitoring capsule delivery devices amid the risk of them failing whilst ...

Novocure has become the latest medtech company to be hit by a cyberattack, with the oncology specialist revealing that ...

As for Alnylam’s marketed med Amvuttra (vutrisiran), approved in ATTR-CM patients last March, the company itself used the ESC Congress to trumpet a subgroup analysis in its pivotal Helios-B trial ...

GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, ...

Natera inked a collaboration deal with biotech Angiex to assess the use of its Signatera blood test, which looks for small ...

Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. | Roche is paying oncology-focused ...

About a year after halving its staff in a clinical push, Arsenal Biosciences is now making a hard pivot, laying off most of its employees and seeking new homes for its assets. ArsenalBio is turning to ...

Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events, Fierce has learned. | Novartis and Bristol Myers Squibb have halted ...

Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to ...

The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline. | ...

As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own ...

AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for chronic hepatitis ...